SynthesisFrontiers in endocrinology2026
Prevalence and risk factors of hyperuricemia and gout in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is one of the most common metabolic diseases worldwide. hyperuricemia (HUA) and gout are common comorbidities in T2DM patients. This systematic review and meta-analysis aimed to estimate the global prevalence of HUA and gout in patients with T2DM and to identify associated risk factors. Methods: A systematic search was conducted in PubMed, Embase, Web of Science, and the Cochrane Library to identify observational studies on HUA/gout in patients with T2DM. Two researchers independently performed literature screening, data extraction, and quality assessment. The quality of included studies was assessed using the Newcastle-Ottawa Scale and the AHRQ Scale. Statistical analyses were performed using Stata 12.0 software. A random-effects model was used to pool prevalence estimates, with subgroup and sensitivity analyses to explore heterogeneity. Publication bias was assessed using Egger's test. Results: Eighty-seven studies comprising 977,573 T2DM patients were included. The pooled prevalence of HUA was 22.0% (95% CI: 20.1-24.0%, 95% PI: 4.9-39.2%), and that of gout was 6.0% (95% CI: 4.4-7.5%). Meta-regression identified geographic region as a significant source of heterogeneity, with the highest HUA prevalence in Africa and North America, and lowest in South America. Risk factors for HUA included impaired renal function, obesity, dyslipidemia, hypertension, metabolic syndrome, and alcohol consumption, while elevated HbA1c was inversely associated with HUA. Male sex was a significant risk factor for gout. Conclusion: The prevalence of HUA and gout is significantly higher in patients with T2DM than in the general population. Impaired renal function, obesity, dyslipidemia, hypertension, MetS, and alcohol consumption are the primary risk factors. Routine serum uric acid monitoring and early screening for high-risk individuals should be incorporated into the clinical management of T2DM. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261359583, identifier CRD420261359583.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.